Please assess the completion status of the following clinical trial:

Trial Title: HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically and/or radiologically confirmed advanced HCC~* Detectable HCV RNA with anti-HCV-positivity~* Life expectancy of at least 3 months~* Willing to use adequate contraception~Exclusion Criteria:~* Pregnant or breastfeeding~* Undetectable HCV RNA~* Uncontrolled hypertension~* Active or clinically significant cardiac disease~* Thrombolic, embolic, venous or arterial events within 6 months of informed consent~* Pulmonary hemorrhage/bleeding event (NCI-CTCAE grade 2 or higher) within 4 weeks before study entry~* Previously untreated or concurrent cancer except cervical cancer in situ, treated basal cell carcinoma or superficial bladder tumor~* Presence of non-healing wound, ulcer or bone fracture~* History of organ allograft~* Known or suspected allergy or hypersensitivity to any of the study drugs~* Any malabsorption condition~* Inability to comply with the protocol and/or not willing or not available for follow up~* Major surgery within 30 days prior to start of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Sorafenib taken orally twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).